BC
Birchview Capital Portfolio holdings
AUM
$101M
This Quarter Return
-15.07%
1 Year Return
+34.62%
3 Year Return
+103.2%
5 Year Return
+107.72%
10 Year Return
+352.1%
AUM
$113M
AUM Growth
+$113M
(-18%)
Cap. Flow
-$10.3M
Cap. Flow
% of AUM
-9.15%
Top 10 Holdings %
Top 10 Hldgs %
80.31%
Holding
57
New
5
Increased
11
Reduced
4
Closed
11
Top Buys
| 1 |
Acadia Pharmaceuticals
ACAD
|
$3.3M |
| 2 |
Biogen
BIIB
|
$1.9M |
| 3 |
Neurocrine Biosciences
NBIX
|
$1.64M |
| 4 |
Gilead Sciences
GILD
|
$1.5M |
| 5 |
Karyopharm Therapeutics
KPTI
|
$1.31M |
Top Sells
| 1 |
CFRX
ContraFect Corporation
CFRX
|
$14.8M |
| 2 |
YTEN
Yield10 Bioscience, Inc. Common Stock
YTEN
|
$2.77M |
| 3 |
DERM
Dermira, Inc.
DERM
|
$1.21M |
| 4 |
WMGI
Wright Medical Group Inc
WMGI
|
$914K |
| 5 |
Myriad Genetics
MYGN
|
$817K |
Sector Composition
| 1 | Healthcare | 95.51% |
| 2 | Energy | 0.77% |
| 3 | Consumer Staples | 0.06% |
| 4 | Consumer Discretionary | 0.04% |
| 5 | Materials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Bristol-Myers Squibb
BMY
$96B
| $43.8M | 38.85% |
785,785
+7,200
| +0.9% | +$401K |
|
|
AXDX
2
DELISTED
Accelerate Diagnostics
AXDX
| $18.3M | 16.21% |
2,193,795
+10,000
| +0.5% | +$83.3K |
|
|
3
Neurocrine Biosciences
NBIX
$13.8B
| $6.41M | 5.68% |
74,000
+19,000
| +35% | +$1.64M |
|
4
QuidelOrtho
QDEL
$1.95B
| $4.78M | 4.24% |
48,844
| – | – |
|
|
5
Acadia Pharmaceuticals
ACAD
$4.38B
| $3.89M | 3.45% |
92,000
+78,000
| +557% | +$3.3M |
|
|
6
Biogen
BIIB
$19.4B
| $3.48M | 3.09% |
11,000
+6,000
| +120% | +$1.9M |
|
|
7
Karyopharm Therapeutics
KPTI
$61.7M
| $2.84M | 2.52% |
148,000
+68,000
| +85% | +$1.31M |
|
|
BMY.RT
8
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $2.69M | 2.38% |
706,848
+7,200
| +1% | +$27.4K |
|
|
VRML
9
DELISTED
Vermillion, Inc.
VRML
| $2.68M | 2.38% |
3,221,933
| – | – |
|
10
United Therapeutics
UTHR
$13.8B
| $1.71M | 1.51% |
18,000
+13,000
| +260% | +$1.23M |
|
|
XLRN
11
DELISTED
Acceleron Pharma Inc.
XLRN
| $1.68M | 1.49% |
18,672
| – | – |
|
|
OXFD
12
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $1.58M | 1.4% |
170,303
| – | – |
|
|
13
Gilead Sciences
GILD
$140B
| $1.5M | 1.33% |
+20,000
| New | +$1.5M |
|
|
CFRX
14
DELISTED
ContraFect Corporation
CFRX
| $1.47M | 1.31% |
255,700
-2,571,303
| -91% | -$14.8M |
|
15
Masimo
MASI
$7.59B
| $1.42M | 1.26% |
8,000
| – | – |
|
|
CCXI
16
DELISTED
ChemoCentryx, Inc.
CCXI
| $1.21M | 1.07% |
30,000
+5,000
| +20% | +$201K |
|
|
EPZM
17
DELISTED
Epizyme, Inc
EPZM
| $931K | 0.83% |
+60,000
| New | +$931K |
|
|
ARNA
18
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $924K | 0.82% |
22,000
| – | – |
|
19
Vanda Pharmaceuticals
VNDA
$279M
| $829K | 0.74% |
80,000
| – | – |
|
|
ALBO
20
DELISTED
Albireo Pharma, Inc. Common Stock
ALBO
| $786K | 0.7% |
48,000
| – | – |
|
|
AMRN
21
Amarin Corp
AMRN
$311M
| $720K | 0.64% |
180,000
+121,000
| +205% | +$484K |
|
22
Harrow
HROW
$1.44B
| $688K | 0.61% |
180,000
| – | – |
|
|
IMGN
23
DELISTED
Immunogen Inc
IMGN
| $648K | 0.57% |
190,000
+10,000
| +6% | +$34.1K |
|
|
EQM
24
DELISTED
EQM Midstream Partners, LP
EQM
| $605K | 0.54% |
51,250
| – | – |
|
25
Arvinas
ARVN
$568M
| $604K | 0.54% |
15,000
-15,000
| -50% | -$604K |
|